Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 2 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 2 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride replenishes intracellular potassium; dextrose provides caloric energy; sodium chloride maintains extracellular fluid osmolality. The combination corrects fluid, electrolyte, and caloric deficits.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion: 0.3% KCl, 10% dextrose, 0.2% NaCl solution administered at 100-125 mL/hour (providing 3-3.75 mEq KCl/hour). Typical adult dose: 10-20 mEq KCl per hour via continuous infusion, not to exceed 20 mEq/hour or 200 mEq/day. Rate adjusted based on serum potassium and clinical response.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Potassium: rapid redistribution half-life ~0.5-1 hour; terminal elimination half-life ~2-4 hours, dependent on renal function and total body potassium stores. Dextrose: negligible (rapidly metabolized; half-life <15 minutes). Sodium: 2-4 hours under normal regulation. Clinical context: half-lives are dose-independent and reflect body's homeostatic control.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Potassium: renal (90% excreted unchanged, primarily via distal tubule and collecting duct secretion; minor fecal loss ~10%). Dextrose: metabolized to CO2 and water (renal excretion of glucose negligible unless hyperglycemia exceeds renal threshold). Sodium: renal (95% excreted unchanged, regulated by aldosterone). Chloride: renal (primarily reabsorbed; excreted as counterion for ammonium or potassium).
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."